Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov 12;8(21):5493-5496.
doi: 10.1182/bloodadvances.2024013962.

Efficacy and tolerance of brexucabtagene autoleucel in adults with R/R B-ALL: a GRAALL study from the DESCAR-T registry

Florence Rabian  1   2 , David Beauvais  3 , Tony Marchand  4   5   6 , Sabine Fürst  7 , Anne Huynh  8 , Eolia Brissot  9 , Sébastien Maury  10 , Ludovic Gabellier  11 , Patrice Chevallier  12 , Michael Loschi  13 , Stéphanie Nguyen  14 , Marie Balsat  15 , Ingrid Lafon  16 , Amandine Fayard  17 , Vincent Camus  18 , Célestine Simand  19 , Niels Moya  20 , Cristina Castilla-Llorente  21 , Magalie Joris  22 , Ana Berceanu  23 , Anne Thiebaut-Bertrand  24 , Véronique Lhéritier  25 , Eve Gehlkopf  26 , Gabrielle Roth-Guépin  27 , Thibaut Leguay  28 , Nicolas Boissel  1   2
Affiliations

Efficacy and tolerance of brexucabtagene autoleucel in adults with R/R B-ALL: a GRAALL study from the DESCAR-T registry

Florence Rabian et al. Blood Adv. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: N.B. received honoraria and research funding from Novartis. F.R. received honoraria from Kite/Gilead. E.B. received honoraria from Novartis. The remaining authors declare no competing financial interests.

Figures

Figure 1.
Figure 1.
Outcome after brexu-cel infusion. Kaplan-Meier curve of survival probability and 95% confidence interval for EFS (A) and OS (B) in the infused cohort. OS according to prior HSCT (C), prior BLIN (D), response to brexu-cel (E), and pre-LD tumor burden (E). (G) Univariate analysis for EFS and OS. ECOG-PS, Eastern Cooperative Oncology Group performance status; NR, not reached.
See this image and copyright information in PMC

References

    1. Shah BD, Ghobadi A, Oluwole OO, et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet. 2021;398(10299):491–502. - PMC - PubMed
    1. Shah BD, Cassaday RD, Park JH, et al. Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3. J Immunother Cancer. 2023;11(8) - PMC - PubMed
    1. Laetsch TW, Maude SL, Rives S, et al. Three-year update of tisagenlecleucel in pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia in the ELIANA trial. J Clin Oncol. 2023;41(9):1664–1669. - PMC - PubMed
    1. Jabbour E, Tholouli E, Sandhu KS, et al. Obecabtagene autoleucel (obe-cel, AUTO1) in adults with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL): Overall survival (OS), event-free survival (EFS) and the potential impact of chimeric antigen receptor (CAR)-T cell persistency and consolidative stem cell transplantation (SCT) in the open-label, single-arm FELIX phase Ib/II study. JCO. 2024;42(suppl 16):6504.
    1. Dourthe M-E, Rabian F, Yakouben K, et al. Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia. Leukemia. 2021;35(12):3383–3393. - PubMed

LinkOut - more resources